Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline

Michael A. Vogelbaum, Paul D. Brown, Hans Messersmith*, Priscilla K. Brastianos, Stuart Burri, Dan Cahill, Ian F. Dunn, Laurie E. Gaspar, Na Tosha N. Gatson, Vinai Gondi, Justin T. Jordan, Andrew B. Lassman, Julia Maues, Nimish Mohile, Navid Redjal, Glen Stevens, Erik Sulman, Martin van den Bent, H. James Wallace, Jeffrey S. WeinbergGelareh Zadeh, David Schiff

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Scopus)

Abstract

PURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. RECOMMENDATIONS Surgery is a reasonable option for patients with brain metastases. Patients with large tumors with mass effect are more likely to benefit than those with multiple brain metastases and/or uncontrolled systemic disease. Patients with symptomatic brain metastases should receive local therapy regardless of the systemic therapy used. For patients with asymptomatic brain metastases, local therapy should not be deferred unless deferral is specifically recommended in this guideline. The decision to defer local therapy should be based on a multidisciplinary discussion of the potential benefits and harms that the patient may experience. Several regimens were recommended for non-small-cell lung cancer, breast cancer, and melanoma. For patients with asymptomatic brain metastases and no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients with one to four unresected brain metastases, excluding small-cell lung carcinoma. SRS alone to the surgical cavity should be offered to patients with one to two resected brain metastases. SRS, whole brain radiation therapy, or their combination are reasonable options for other patients. Memantine and hippocampal avoidance should be offered to patients who receive whole brain radiation therapy and have no hippocampal lesions and 4 months or more expected survival. Patients with asymptomatic brain metastases with either Karnofsky Performance Status # 50 or Karnofsky Performance Status, 70 with no systemic therapy options do not derive benefit from radiation therapy. Additional information is available at www.asco.org/neurooncology-guidelines.

Original languageEnglish
Pages (from-to)492-516
Number of pages28
JournalJournal of Clinical Oncology
Volume40
Issue number5
Early online date21 Dec 2021
DOIs
Publication statusPublished - 10 Feb 2022

Bibliographical note

Publisher Copyright:
© 2021 by American Society of Clinical Oncology

Fingerprint

Dive into the research topics of 'Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline'. Together they form a unique fingerprint.

Cite this